Salacia extract improves post-prandial glucose and insulin response

ISRCTN ISRCTN84979645
DOI https://doi.org/10.1186/ISRCTN84979645
Secondary identifying numbers OAHT_SE2015
Submission date
17/02/2016
Registration date
19/02/2016
Last edited
31/07/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
The amount of sugar (glucose) in the blood is controlled by a hormone called insulin. If you have diabetes, either the body does not produce enough insulin or the insulin produced doesn't work properly, leading to high blood glucose levels. Extracts of the Salacia species of herb from roots, stems, and leaves are used for the treatment of diabetes in Asia. The aim of this study is to examine the effect of different doses of a new form of Salacia extract (Salacia Chinensis, SCE) on the glucose and insulin response to oral sucrose (sugar) solution in healthy individuals (South Asian Population).

Who can participate?
People aged 18-55, with body mass index (BMI) 24.5 to 29.5 kg/m2

What does the study involve?
Participants are given sucrose solution and Salacia extract, and blood samples are collected at the start and after 30, 60, 90, 120 and 180 minutes to assess their blood glucose and insulin response. Different doses of Salacia extract are tested with a 7-day break in between treatments and results are compared with a placebo (dummy) treatment.

What are the possible benefits and risks of participating?
We will find out whether Salacia supplementation helps to maintain or lower blood glucose and insulin levels after sucrose solution administration. This will help them to understand how to manage blood glucose levels and helps in diabetes condition. Pain associated due to multiple times of blood collection to assess blood glucose and insulin levels.

Where is the study run from?
Semler Research Center (India)

When is the study starting and how long is it expected to run for?
July to December 2015

Who is funding the study?
Atlantic Canada Opportunities Agency

Who is the main contact?
Dr Vijaya Juturu

Contact information

Dr Vijaya Juturu
Scientific

OmniActive Health Technologies Inc.
67 East Park Place, Suite 500
Morristown
07960
United States of America

ORCiD logoORCID ID 0000-0002-7397-715X

Study information

Study designRandomized double-blind placebo-controlled cross-over study
Primary study designInterventional
Secondary study designRandomised cross over trial
Study setting(s)Other
Study typePrevention
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleSalacia extract improves post-prandial glucose and insulin response: a randomized double-blind placebo-controlled, cross-over study in healthy volunteers
Study hypothesisStudies indicate that Salacia extracts modulate multiple targets that influence carbohydrate and lipid metabolism. This study is to examine the effect of differing doses of a novel form of Salacia extract (Salacia Chinensis, SCE) on glucose and insulin response to an oral sucrose load in healthy individuals (South Asian Population).
Ethics approval(s)Sri Venkateswara Hospital Ethics Committee , India, 08/06/2015, ref: S-15-1203
ConditionNot Applicable
InterventionParticipants will be randomly assigned to ingest Salacia extract at dosages of 200 mg SCE , 300 mg SCE and 500 mg SCE (OmniLeanTM) or placebo (PLA) in a single-center, double-blind, randomized, placebo-controlled four-way cross-over design. Washout period between treatment periods was 7 days. Plasma glucose and plasma insulin responses after 0, 30, 60, 90, 120, 180 min of ingesting oral sucrose standard solution and area under curve for glucose (AUCglucose) and insulin response (AUCinsulin) will be calculated. ANOVA and paired t-tests will be used to examine differences between treatments and over baseline.
Intervention typeSupplement
Primary outcome measureGlucose and insulin responses after 0, 30, 60, 90, 120 and 180 min
Secondary outcome measuresAUC glucose and AUC insulin
Overall study start date30/07/2015
Overall study end date30/12/2015

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
Lower age limit18 Years
Upper age limit55 Years
SexBoth
Target number of participants40
Participant inclusion criteria1. Male and female subjects aged 18-55 years of age (both ages inclusive), of BMI 24.5 to 29.5 Kg/ m2
2. Participants required to avoid all dietary supplements, OTC or any foods interfere with post-prandial glucose and insulin before and throughout the study period and not allowed to drink alcoholic beverages or caffeine during the period of the study
3. Non smokers
4. No pregnant and lactating women
5. Signed consent form
Participant exclusion criteria1. Participation in any bioavailability/bioequivalence/pharmacokinetic study or received an investigational drug within a period of 3 calendar months prior to check in of period one
2. Use of dietary supplements to reduce body weight or metabolic health management at least 30 days before check in of period one
3. Use of hormone replacement therapy for a period of 6 calendar months prior to check in of period one
4. History of drug abuse, or alcohol dependence or abuse
5. History of any allergies (asthma, urticaria) including drug allergies
6. Known hypersensitivity or allergy to Salacia extract or any of the excipients or related drugs.
7. Smokers, prescriptions, chronic conditions such as hypertension, diabetes , inflammatory disorders, cardiovascular disease and cancer etc
Recruitment start date02/08/2015
Recruitment end date08/09/2015

Locations

Countries of recruitment

  • India

Study participating centre

Semler Research Center
Semler Research Center Pvt. Ltd
P A Arcade, No 21, 22, 23
Kodigehalli Main Road
Sahakarnagar
Bangalore
560092
India

Sponsor information

OmniActive Health Technologies Ltd (Canada)
Industry

c/o Dr Jayant Deshpande
OmniActive Health Technologies (Canada) Limited
Bio commons Research Park in Charlottetown
Prince Edward Island
C1A 8R8
Canada

ROR logo "ROR" https://ror.org/05rga6m50

Funders

Funder type

Government

Atlantic Canada Opportunities Agency
Government organisation / Local government
Alternative name(s)
Agence de Promotion Économique du Canada Atlantique, ACOA Canada, ACOA
Location
Canada

Results and Publications

Intention to publish date30/08/2016
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planTo be confirmed at a later date
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/07/2016 Yes No

Editorial Notes

31/07/2018: Publication reference added.